Mirabegron

beta3-Adrenergic Agonist — GENITO URINARY SYSTEM AND SEX HORMONES

Key facts

Mirabegron is an ofp drug in the beta3-Adrenergic Agonist class catalogued in DrugCentral. It was first approved by the FDA in 2012. Its mechanism of action is classified as Adrenergic beta3-Agonists, Cytochrome P450 2D6 Inhibitors and Cytochrome P450 3A Inhibitors. DrugCentral lists 5 molecular targets, including Adrb3, Adrb3 and ADRB3. Recorded indications include Bladder muscle dysfunction - overactive.

• Approval status: ofp (first approved 2012 by the FDA).
• Drug class: beta3-Adrenergic Agonist.
• Mechanism of action: Adrenergic beta3-Agonists; Cytochrome P450 2D6 Inhibitors; Cytochrome P450 3A Inhibitors.
• Molecular targets: Adrb3, Adrb3, ADRB3 and ADRB2 (5 listed in DrugCentral).
• Indications: Bladder muscle dysfunction - overactive.
• ATC code: G04BD12 (Drugs for urinary frequency and incontinence).
• Molecular formula: C21H24N4O2S; molecular weight 396.52 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

• Bladder muscle dysfunction - overactive

Contraindications (1)

• Hypertensive disorder

Mechanism & targets

• Mechanism of action (MoA): Adrenergic beta3-Agonists; Cytochrome P450 2D6 Inhibitors; Cytochrome P450 3A Inhibitors; P-Glycoprotein Inhibitors
• Established pharmacologic class: beta3-Adrenergic Agonist

Molecular targets (5)

Target	Gene	Action	Activity
Beta-3 adrenergic receptor	Adrb3	agonist	EC50 9.30
Beta-3 adrenergic receptor	Adrb3	agonist	EC50 7.70
Beta-3 adrenergic receptor	ADRB3	agonist	EC50 7.65
Beta-2 adrenergic receptor	ADRB2	agonist	EC50 5.20
Beta-2 adrenergic receptor	Adrb2	agonist	EC50 5.00

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
2012-06-28	FDA	—	APGDI

ATC classification

ATC code	Therapeutic hierarchy
G04BD12	GENITO URINARY SYSTEM AND SEX HORMONES › UROLOGICALS › UROLOGICALS › Drugs for urinary frequency and incontinence

Pharmacogenomics

Drug-label and guideline annotations from PharmGKB and CPIC.

• EMA label: CYP2D6 · No Clinical PGx
• FDA label: CYP2D6 · Informative PGx
• HCSC label: CYP2D6 · No Clinical PGx
• Swissmedic label: CYP2D6 · Informative PGx

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Blepharospasm	1142.0
Taste disorder	952.9
Onychomadesis	804.2
Epilepsy	744.3
Nail disorder	665.7
Breast cancer stage III	645.2
Peripheral venous disease	633.7
Back injury	604.6
Gastrooesophageal reflux disease	577.2
Facet joint syndrome	563.9
Bursitis	530.4
Onychomycosis	528.7

Chemical structure

• Molecular formula: C₂₁H₂₄N₄O₂S
• Molecular weight: 396.52 g/mol
• CAS number: —
• InChIKey: PBAPPPCECJKMCM-IBGZPJMESA-N
• PubChem CID: 9865528

NC1=NC(CC(=O)NC2=CC=C(CCNC[C@H](O)C3=CC=CC=C3)C=C2)=CS1

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Mirabegron used for?

DrugCentral lists the following indications for Mirabegron: Bladder muscle dysfunction - overactive.

How does Mirabegron work?

Mirabegron is classified as Adrenergic beta3-Agonists, Cytochrome P450 2D6 Inhibitors and Cytochrome P450 3A Inhibitors; its molecular targets in DrugCentral include Adrb3 (agonist), Adrb3 (agonist), ADRB3 (agonist) and ADRB2 (agonist).

When was Mirabegron first approved?

Mirabegron was first approved by the FDA in 2012.

What drug class does Mirabegron belong to?

Mirabegron is in the beta3-Adrenergic Agonist class.

What is the chemical formula of Mirabegron?

Mirabegron has the molecular formula C21H24N4O2S and a molecular weight of 396.52 g/mol.

Sources

• DrugCentral drug card 4382 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL2095212 — compound record and bioactivity
• PubChem CID 9865528 — chemical identifiers
• DrugBank DB08893 — drug record
• FDA UNII MVR3JL3B2V — substance identity
• DailyMed: FDA labels for Mirabegron — current prescribing information (label search)
• UniProt P13945 (ADRB3) — target protein
• UniProt P07550 (ADRB2) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
• PharmGKB / CPIC — pharmacogenomic label annotations

How this page is built: methodology · editorial policy & corrections.